Biotech RadarJobs updated

COMPANY

AnaptysBio

HQ: San Diego, CA source · anaptysbio.com ↗ · West Coast

Clinical Phase 2

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

Keywords: Ulcerative Colitis Atopic Dermatitis Eczema Rheumatoid Arthritis Eosinophilic Asthma Peanut Allergy Atopic Dermatitis Alopecia Areata Chronic Rhinosinusitis Rosnilimab Etokimab ANB032

8Trials (company is sponsor)

Timeline

  1. Partnership Partnership / licensing: $15M (upfront, as published), announced Feb 3, 2025. Source: SEC filing. source ↗
  2. Trial start Phase 2: A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA) source ↗
  3. Trial start Phase 2: A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR) source ↗
  4. Trial start Phase 2: This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD). source ↗
  5. Trial start Phase 2: A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata source ↗
  6. Trial start Phase 2: Etokimab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) source ↗
  7. Trial start Phase 2: Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic Dermatitis source ↗
  8. Trial start Phase 2: Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma source ↗
  9. Trial start Phase 2: Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut Allergy source ↗

Funding

Last 2 years.

Clinical trials (lead sponsor) 8

RecordTitlePhaseStatusStartPrimary completion
NCT06127043A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)Phase 2Active, not recruitingDec 4, 20232026-01 (estimated)
NCT05935085This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).Phase 2TerminatedJun 13, 2023Oct 16, 2024 (actual)
NCT06041269A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)Phase 2Active, not recruitingAug 31, 2023Nov 29, 2024 (estimated)
NCT03469934Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic AsthmaPhase 2CompletedNov 14, 2017Oct 30, 2018 (actual)
NCT02920021Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut AllergyPhase 2CompletedJan 26, 2017Mar 30, 2018 (actual)
NCT03533751Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic DermatitisPhase 2CompletedJun 19, 2018Dec 3, 2019 (actual)
NCT05205070A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia AreataPhase 2Unknown status (ClinicalTrials.gov)Dec 22, 2021Jan 19, 2023 (estimated)
NCT03614923Etokimab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)Phase 2CompletedNov 29, 2018Sep 2, 2020 (actual)
Feedback